acquired
Stage
1
Investors
About
Aldena Therapeutics develops siRNA-based RNA interference therapies targeting dermatological conditions, focusing on locally delivered skin treatments with infrequent dosing. It operates as a fully owned subsidiary of Alys Pharmaceuticals.
Explore Aldena Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.